Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-Derived CMV-pp65 CTLs for CMV After HSCT
NCT01646645Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2012
- Primary completion
- Dec 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of cytomegalovirus pp65-specific cytotoxic t lymphocytes in cytomegalovirus infection (CMV), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2012; status: completed.
02
Drugs
cytomegalovirus pp65-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01646645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646645.